CODX Co-Diagnostics Inc
Market Cap
97.39M
Day’s Range
52W Range
Volume (3M)
146.79K
Price-Earnings Ratio
6.83
Revenue
53.22M
Co-Diagnostics Inc Latest News
About Co-Diagnostics Inc
Co-Diagnostics Inc is an American biotechnology company primarily involved in the development, manufacture, and sale of molecular diagnostics technology. Operating internationally, the firm focuses on providing simple, fast, and accurate diagnostic tests for a range of diseases, relying on cutting-edge technology for enhanced detection of genetic material. The firm was founded in 2013 and is based in Salt Lake City, Utah.
The company’s range of Logix SmartTM kits are used to detect mycobacteria tuberculosis (MTB), Zika virus, ZDC, COVID-19, and SARS-CoV-2. The firm is also involved in the development of vector control solutions, creating diagnostic tests that can be used to test populations of mosquitos and other organisms known to act as vectors in the spread of infectious diseases. In addition, Co-Diagnostics Inc is involved in testing programmes in agriculture, primarily in the genetic enhancement of agricultural products to ensure safe but productive crops worldwide.
As well as its Salt Lake City headquarters, the firm has a facility located in Gujarat, India. The CoSara Clinical Laboratories facility is situated within the Ambalal Sarabhai Foundation, with the intention to expand research and development and manufacturing activities, as well as offering clinical services. Co-Diagnostics Inc is listed on the NASDAQ under the ticker CODX.
Consider adding CODX stock to your eToro watchlist.
Show More101
Employees
Salt Lake City, Utah, US
HQ
2013
Founded
Dwight Howard Egan
CEO
Upcoming Earnings
23
MAR
REPORTS
Co-Diagnostics Inc Q4 2022 earnings report is expected to be released after market open
People Also Bought
- GSAT Globalstar 0.71%
- XXII 22nd Century Group Inc. 1.87%
- AYTU Aytu BioScience Inc 1.38%
- NHWK NightHawk Biosciences Inc -2.59%
- IZEA IZEA Worldwide Inc 2.08%
- VXRT Vaxart Inc 0.92%
- ADVM Adverum Biotechnologies Inc 4.11%
- SURF Surface Oncology Inc 0.15%